Skip to content
etf.net

BIB vs WX

ProShares Ultra Nasdaq Biotechnology

BIBBNasdaq

Corgi All World 2x Daily ETF

WXCCboe

Overlap

0.0%by weight

Expense ratio

WX −0.75pt a year

BIB0.95%WX0.20%

Avg volume · 30D

BIB 36.8×the volume

BIB10.5KWX285

BIB vs WX Performance

Jul 31, 2026 – Oct 30, 2026

+24.9%BIB−3.2%WX

Jul 31, 2026 to Oct 30, 2026. BIB +24.9%. WX −3.2%. Use the arrow keys to read each point.10%20%30%Jul 2026Sep 2026Oct 2026
Expense ratio
BIB 0.95%
WX 0.20%, better
Fund size
BIB $104M
WX $1M
1Y total return
BIB +68.9%
WX No data
Yield (12M)
BIB 0.19%
WX No data
Holdings
BIB 247
WX 1
Avg volume (30D)
BIB 10.5K sh, better
WX 285 sh
NAV per share
BIB $120.62
WX $22.96
52W range

ETF.net Grade

BIB: Cost 51, Risk 70, Mission not scored, Tradability 84, Holdings 60, Durability 75. WX: Cost 100, Risk 71, Mission not scored, Tradability 31, Holdings not scored, Durability 23.
Pillar letters and Scores for BIB, WX, with each pillar’s weight
PillarBIBWX
Cost30% weightC51A100Higher
Mission25% weightNot scoredNot scored
Risk15% weightA70A71Higher
Tradability15% weightA84HigherD31
Holdings10% weightB60Not scored
Durability5% weightA75HigherF23

Rank among Leveraged Long (2x & Other) funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. BIB and WX are both graded against the same 95 Leveraged Long (2x & Other) funds, so their Grades compare head to head.

Leveraged Long (2x & Other)⁠

Category · 95 funds
See all 95 ›

BIB ranks 8th and WX 37th of 95 funds in the Leveraged Long (2x & Other) Category.

  1. Rank 7BUJBProShares Ultra High YieldScore 65
  2. Rank 8BBIBProShares Ultra Nasdaq BiotechnologyScore 64
  3. Rank 9BMVVProShares Ultra MidCap400Score 63
  4. Rank 37CWLDULeverage Shares 2x Long World SScore 40
  5. Rank 37CWXCorgi All World 2x Daily ETFScore 40
  6. Rank 37CXBIXCorgi U.S. Biotech 2x Daily ETFScore 40

Our read on each fund

ETF.net Research

BIBBProShares Ultra Nasdaq Biotechnology

WXCCorgi All World 2x Daily ETF

In short

BIB Biotech with the dial at 2x, not 3x. Since 2010 BIB has aimed at twice the daily move of the Nasdaq Biotechnology Index, a modified cap-weighted set of Nasdaq-listed biotech and pharma names, reset fresh every single day.

WX No data

Stated mandate

BIB The Fund seeks daily investment results, before fees and expenses, that correspond to two times the daily performance of the Nasdaq Biotechnology Index.

WX No data

Why people hold it

  • BIB Aims for two times the daily move of the Nasdaq Biotechnology Index. Magnified biotech exposure through one ticker in a regular brokerage account, no margin agreement needed.proshares.com
  • The benchmark dates to 1993: Nasdaq-listed biotech and pharma, modified cap-weighted, roughly 300 stocks. Industry-wide exposure, not a handful of lottery tickets.nasdaqomx.comnasdaqomx.com 2
  • 0.95% net of a waiver through September 30, 2027, against a 1.17% gross. Near the category median and level with ProShares stablemate DDM at 0.95%.
  • Live since 2010 through several biotech boom-and-bust cycles, and it stands among the stronger implementations in a crowded leveraged-bull field.

WX No data

Worth knowing

  • BIB Daily reset. Hold past one day and compounding takes over: returns can differ in amount, and even direction, from 2x the index over that stretch.proshares.com
  • One industry, doubled. Trial readouts and FDA decisions move biotech hard, and this fund is built to amplify those days in both directions.proshares.com
  • Among the lighter-traded, smaller funds in its category, so spreads and order size matter more here than with the headline leveraged names.

WX No data

Full BIB profile⁠

Full WX profile⁠

BIB vs WX Holdings

How BIB and WX differ

Overlap by weight

0.0%

Shared holdings make up 0.0% of BIB and 0.0% of WX.

Level by level

  • Holdings0 in both0.0%
  • Countryby domicile95.2%
  • Asset classEquity100%

Sector

No Sector split for WX.

Country, concentration and asset class

Country by domicile

Country weights in BIB and WX, widest gap first
CountryMore in BIBMore in WX
United StatesWX +4.8 points
United KingdomBIB +2.0 points
FranceBIB +0.9 points
CanadaBIB +0.5 points
Other countries (9)BIB +1.5 points

Concentration

Weight in the 10 largest Holdings

  • BIB66.4%
  • WX198.9%

Securities held

  • BIB246
  • WX0

Asset class

BIB
Equity
WX
Equity

Holdings

  • Only in BIB246
  • In both0
  • Only in WX0

Only in BIB

246 securities, 76.8% of BIB by weight

  • Proshares Genius Mny Mkt Etf16.41%
  • Gilead Sciences Inc5.49%
  • Amgen Inc5.10%

Only in WX

0 securities, 0.0% of WX by weight

Weight gaps

BIB and WX share no securities.

All 274 BIB holdings⁠All 15 WX holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

BIB vs WX Cost

Overpaying BIB vs WX

$13,714

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BIB 0.95%

    $17,869

  • WX 0.20%

    $4,155

$10,000
30 years

Cost over time

  • BIB 0.95%
  • WX 0.20%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K$20K051015202530BIB $17,869WX $4,155

Year by year

YearBIBWXOverpaying
10$1,678$365$1,313
20$6,322$1,421$4,901
30$17,869$4,155$13,714

Expense ratio

  • 0.95%BIB
  • 0.20%WX, cheaper
  • Middle half of Leveraged Long (2x & Other) funds
  • Median 0.95%

WX cheapest of 95 funds

BIB 32nd cheapest of 95 funds

BIB vs WX Dividends

Last 12 months to Oct 30, 2026
Yield (12M)
BIB 0.19%
WX No data
Payout (12M)
BIB $0.22
WX None
Last payment
BIB $0.08
WX No data
Ex-dividend
BIB Sep 23, 2026
WX No data
Paid on
BIB Sep 29, 2026
WX No data
Frequency
BIB Twice a year
WX No data

Distribution history

Per share, 2017 to 2026, same scale for both

BIBTwice a year · 12 paymentsAll BIB payments⁠
One bar per payment. 12 payments from 2017 to 2026 YTD. Dec 22, 2022 $0.02; Dec 20, 2023 $0.04; Mar 20, 2024 $0.04; Jun 26, 2024 $0.26; Sep 25, 2024 $0.15; Dec 23, 2024 $0.40; Mar 26, 2025 $0.13; Jun 25, 2025 $0.17; Sep 24, 2025 $0.18; Dec 24, 2025 $0.13; Mar 25, 2026 $0.0071; Sep 23, 2026 $0.08. Use the arrow keys to read each point.$0$0.252017202020232026YTD
WXAll WX payments⁠

No distribution history available.

BIB vs WX Risk

Fall from peak · 5 years

This chart needs five years of history for both funds.

Risk facts

VolatilityStd dev, 3 years
BIB 33.9%WX No data
Return per unit of riskSharpe ratio, 3 years
BIB 1.12WX No data
Worst fallMax drawdown, 5 years
BIB −61.8%WX No data
Market sensitivityBeta, 5 years
BIB 1.20WX 2.76

Popular comparisons

  • BIBBvsQLDA

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra QQQ

    Expense ratio
    0.95% · 0.89%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • WXCvsQLDA

    Corgi All World 2x Daily ETF · ProShares Ultra QQQ

    Expense ratio
    0.20% · 0.89%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BIBBvsUYGA

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra Financials

    Expense ratio
    0.95% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • WXCvsUYGA

    Corgi All World 2x Daily ETF · ProShares Ultra Financials

    Expense ratio
    0.20% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BIBBvsROMA

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra Technology

    Expense ratio
    0.95% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • WXCvsROMA

    Corgi All World 2x Daily ETF · ProShares Ultra Technology

    Expense ratio
    0.20% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.